U.S. Markets open in 6 hrs 33 mins

Allergan plc (AGN)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
224.16+3.50 (+1.59%)
At close: 4:02PM EDT
People also watch
  • Thurston, you are truly a sick person, you should know that help is needed. Soon you will be telling the board how much you have made shorting the stock although by then the stock will be in the high 2 hundreds, or low 3 hundreds. Your one sick individual, no question about that.
  • Thurston says, "I see one positive geese that is a long shot and it will take a long time to play out but there is an inverse shoulder pattern". I see a second chance called the Thurston head up the #$%$ pattern which will also bring any stock he mocks upward. I'll see you at 225 before AGN ever hits 215, even ex-dividend.
  • poor Thurston. When did Allergan fire You? trouble getting a new job? I can see why
  • Thurston may just be using his noose this afternoon seeing hasn't posted in almost an hour.
  • Thurston must have covered his million share short this morning, driving the price up.
  • Noose tightening around shorts. Trapped like rats.
  • It looks like the market likes this financial engineering move...It's above my pay grade to understand it. I'm betting we've seen the bottom for 2017, barring any political disruptions.
  • it get higher
  • what sell it a pull back you should know that if you are a trader stock don't just up up up
  • it look like it holding
  • Looks like 220 may be the bottom for now, sorry Thurston.
  • JPM upgrade with PT of $300. Buy Agn through 7% yielding Agn preferred.
  • So, "Tuna" is "Johnny" is "Thurston"? I just went back and reviewed older postings and the language is too similar to deny the relationship amongst at least these three. I have "Thurston" muted so will not see the ramblings from this poster, but I knew something sounded familiar with the ravings.
  • JPMorgan bullish on Allergan, sees 37% upside
    May 19, 2017 8:18 AM ET |By: Douglas W. House, SA News Editor
    •JPMorgan's Chris Schott says the 8% pullback in Allergan (NYSE:AGN) since its Q1 earnings release is a buying opportunity because its results will become "less controversial" throughout the remainder of the year as its business settles down after the sale of its generics business last year to Teva. Several "meaningful" catalysts are ahead in 2018 (OVERWEIGHT/$300).
  • you really personal don't like agn
  • Wow! This Thurston person is really obsessed and quite possibly insane. I am glad that you are making money on this stock. But, your obsession is over the top! I do have a serious question, however. Did you lose your mind a little at a time, or did you go crazy quickly? Stop with the rants and take your own advice -- move along.
  • No reason to cover a smsll oversold rally which never lasts. AGN has broken all technical support
  • AGN tanked after earnings exactly how I said it would 'n thurston was 100% correct. The morning of earnings the geese were going bananas saying I was wrong and look how greatceverything was. I saw the truth and the numbers were terrible and EXACTLY what I said they would be!! Down went the flying pig agn
  • TIMBER!!! I can't stop laughing what idiots buy the open when I tell you to sell.
  • Zero interest in this hog besides looking for. Odd to hit as institutions. Infinite to dump it with fervor